State Street Corp Adaptimmune Therapeutics PLC Transaction History

State Street Corp

$2.47 Trillion
Q4 2024

A detailed history of State Street Corp transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, State Street Corp holds 400,079 shares of ADAP stock, worth $220,043. This represents 0.0% of its overall portfolio holdings.

Number of Shares

400,079

Previous 396,792 0.83%

Holding current value

$220,043

Previous $376,000 42.55%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Feb 14, 2025	BUY	$0.54 - $0.95 $1,774 - $3,122	3,287 Added 0.83%	400,079 $216,000
Q3 2024 Nov 14, 2024	BUY	$0.92 - $1.39 $5,419 - $8,188	5,891 Added 1.51%	396,792 $376,000
Q2 2024 Aug 14, 2024	BUY	$0.83 - $1.47 $65,041 - $115,193	78,363 Added 25.07%	390,901 $383,000
Q1 2024 May 15, 2024	BUY	$0.7 - $1.75 $5,041 - $12,603	7,202 Added 2.36%	312,538 $493,000
Q4 2023 Feb 14, 2024	BUY	$0.43 - $0.79 $2,681 - $4,925	6,235 Added 2.08%	305,336 $241,000
Q3 2023 Nov 14, 2023	BUY	$0.73 - $1.04 $5,932 - $8,452	8,127 Added 2.79%	299,101 $233,000
Q2 2023 Aug 14, 2023	BUY	$0.9 - $1.51 $5,609 - $9,411	6,233 Added 2.19%	290,974 $267,000
Q1 2023 May 15, 2023	BUY	$1.06 - $2.16 $16,899 - $34,436	15,943 Added 5.93%	284,741 $310,000
Q4 2022 Feb 14, 2023	SELL	$1.05 - $2.53 $42,525 - $102,464	-40,500 Reduced 13.09%	268,798 $392,000
Q3 2022 Nov 15, 2022	SELL	$1.06 - $2.41 $60,660 - $137,917	-57,227 Reduced 15.61%	309,298 $332,000
Q2 2022 Aug 15, 2022	SELL	$1.33 - $2.28 $364,546 - $624,936	-274,095 Reduced 42.79%	366,525 $623,000
Q1 2022 May 16, 2022	BUY	$1.73 - $4.06 $44,334 - $104,045	25,627 Added 4.17%	640,620 $1.32 Million
Q4 2021 Feb 14, 2022	BUY	$3.5 - $5.68 $167,244 - $271,413	47,784 Added 8.42%	614,993 $2.31 Million
Q3 2021 Nov 15, 2021	BUY	$3.44 - $6.37 $1.06 Million - $1.96 Million	307,627 Added 118.51%	567,209 $2.94 Million
Q2 2021 Aug 16, 2021	SELL	$3.86 - $5.78 $570,913 - $854,890	-147,905 Reduced 36.3%	259,582 $1.11 Million
Q1 2021 May 17, 2021	BUY	$4.9 - $6.83 $230,368 - $321,105	47,014 Added 13.04%	407,487 $2.16 Million
Q4 2020 Feb 16, 2021	BUY	$4.0 - $9.2 $618,764 - $1.42 Million	154,691 Added 75.17%	360,473 $1.94 Million
Q3 2020 Nov 10, 2020	BUY	$7.66 - $10.78 $257,000 - $361,679	33,551 Added 19.48%	205,782 $1.64 Million
Q2 2020 Aug 14, 2020	BUY	$2.58 - $12.1 $444,355 - $2.08 Million	172,231 New	172,231 $1.72 Million

Others Institutions Holding ADAP

# of Institutions

Shares Held

123M

Call Options Held

34.2K

Put Options Held

16.3K

View Full List

About Adaptimmune Therapeutics PLC

Ticker ADAP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 163,370,000
Market Cap $89.9M
Description
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...

More about ADAP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account

State Street Corp Adaptimmune Therapeutics PLC Transaction History